<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856085</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-2218-1006</org_study_id>
    <nct_id>NCT04856085</nct_id>
  </id_info>
  <brief_title>Study of VIR-2218 + VIR-3434 in Subjects With Chronic Hepatitis B Virus Infection</brief_title>
  <acronym>MARCH</acronym>
  <official_title>A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of VIR-2218 + VIR-3434 in Subjects With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vir Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will&#xD;
      receive VIR-2218+ VIR-3434 and will be assessed for safety, tolerability, and efficacy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with post-treatment lab abnormalities as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving undetectable hepatitis B surface antigen (HBsAg) and sustained suppression of HBV DNA [target not detected (TND)] &gt;/= 24 weeks after discontinuation of all treatment, including NRTIs</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute serum HBsAg and change from baseline across all timepoints in the study</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serum HBsAg loss (undetectable HBsAg) at any timepoint</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve the nadir and maximum reduction of serum HBsAg from baseline</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with serum HBsAg loss (defined as undetectable HBsAg)</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For hepatitis B e-antigen (HBeAg)-positive subjects: Proportion of subjects with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For HBeAg-positive subjects: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clast</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCexp</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Î»z</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation</measure>
    <time_frame>Up to 68 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects meeting criteria for NRTI retreatment</measure>
    <time_frame>Up to 116 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Cohort 1a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-2218</intervention_name>
    <description>VIR-2218 given by subcutaneous injection</description>
    <arm_group_label>Cohort 1a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 2a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 3a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 4a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 5a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 6a (VIR-2218 + VIR-3434)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-3434</intervention_name>
    <description>VIR-3434 given by subcutaneous injection</description>
    <arm_group_label>Cohort 1a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 2a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 3a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 4a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 5a (VIR-2218 + VIR-3434)</arm_group_label>
    <arm_group_label>Cohort 6a (VIR-2218 + VIR-3434)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ages 18 - &lt;66 years&#xD;
&#xD;
          -  Chronic HBV infection for &gt;/= 6 months&#xD;
&#xD;
          -  On NRTI therapy for &gt;/= 2 months at the time of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant chronic or acute medical condition that makes the&#xD;
             participant unsuitable for participation&#xD;
&#xD;
          -  Significant fibrosis or cirrhosis&#xD;
&#xD;
          -  History or evidence of drug or alcohol abuse&#xD;
&#xD;
          -  History of chronic liver disease from any cause other than chronic HBV infection&#xD;
&#xD;
          -  History of hepatic decompensation&#xD;
&#xD;
          -  History of anaphylaxis&#xD;
&#xD;
          -  History of allergic reactions to monoclonal antibodies or antibody fragments&#xD;
&#xD;
          -  History of immune complex disease&#xD;
&#xD;
          -  Active infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or&#xD;
             hepatitis Delta virus (HDV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Inquiry</last_name>
    <phone>415-654-5281</phone>
    <email>clinicaltrials@vir.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49421</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Batu Caves</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kajang</city>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chiayi City</city>
        <zip>60041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Taichung City</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>08132</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>London</city>
        <zip>E1 4NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Romania</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B Virus</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

